MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder

Not Applicable
Completed
Conditions
Anxiety Disorders
Interventions
First Posted Date
2008-07-15
Last Posted Date
2008-10-03
Lead Sponsor
Pfizer
Target Recruit Count
169
Registration Number
NCT00715039
Locations
🇺🇸

Pfizer Investigational Site, Cincinnati, Ohio, United States

Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus

Phase 1
Completed
Conditions
Lupus Erythematosus, Systemic
Interventions
Drug: SBI-087
First Posted Date
2008-07-14
Last Posted Date
2018-12-07
Lead Sponsor
Pfizer
Target Recruit Count
30
Registration Number
NCT00714116
Locations
🇺🇸

Arthritis & Rheumatology Care Center, South Miami, Florida, United States

🇺🇸

MRA Clinical Research, South Miami, Florida, United States

🇺🇸

Miami Research Associates, South Miami, Florida, United States

and more 3 locations

Registry For Patients Treated With BeneFix In Usual Care Setting In Germany

Completed
Conditions
Hemophilia B
Interventions
First Posted Date
2008-07-14
Last Posted Date
2018-10-25
Lead Sponsor
Pfizer
Target Recruit Count
80
Registration Number
NCT00714415
Locations
🇦🇹

Allgemeines Krankenhaus Linz, Kinderklinik, Linz, Austria

🇩🇪

Werlhof-Institut für Haemostaseologie GmbH, Hannover, Niedersachsen, Germany

🇩🇪

Klinikum der Martin-Luther-Universitaet Halle-Wittenberg, Halle, Germany

and more 18 locations

Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase

Phase 3
Completed
Conditions
Gaucher Disease
Interventions
First Posted Date
2008-07-10
Last Posted Date
2018-10-04
Lead Sponsor
Pfizer
Target Recruit Count
31
Registration Number
NCT00712348
Locations
🇮🇱

Shaare Zedek Medical Center, Jerusalem, Israel

🇬🇧

Royal Free Hospital, London, United Kingdom

🇬🇧

Lysosomal Disorders Service, Addenbrookes Hospital NHS Trust, Cambridge, United Kingdom

and more 7 locations

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

Phase 1
Completed
Conditions
Advanced Solid Tumors
Non Small Cell Lung Cancer
Interventions
First Posted Date
2008-07-10
Last Posted Date
2008-11-11
Lead Sponsor
Pfizer
Target Recruit Count
49
Registration Number
NCT00712504
Locations
🇺🇸

Pfizer Investigational Site, Madison, Wisconsin, United States

Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings

Completed
Conditions
Psoriasis
Interventions
First Posted Date
2008-07-02
Last Posted Date
2015-07-27
Lead Sponsor
Pfizer
Target Recruit Count
926
Registration Number
NCT00708708
Locations
🇩🇪

Westfaelische Wilhelms-Universitaet Muenster, Zentr. f. Derm, Muenster, NRW, Germany

Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia

Phase 2
Terminated
Conditions
Pneumonia, Bacterial
Interventions
Drug: tigecycline
Drug: imipenem/cilastatin
First Posted Date
2008-06-30
Last Posted Date
2012-07-10
Lead Sponsor
Pfizer
Target Recruit Count
108
Registration Number
NCT00707239
Locations
🇨🇳

Pfizer Investigational Site, Taipei, Taiwan

A Study of PF-04217903 in Patients With Advanced Cancer

Phase 1
Terminated
Conditions
Neoplasms
Interventions
First Posted Date
2008-06-27
Last Posted Date
2012-06-25
Lead Sponsor
Pfizer
Target Recruit Count
16
Registration Number
NCT00706355
Locations
🇺🇸

Pfizer Investigational Site, Detroit, Michigan, United States

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

Phase 1
Completed
Conditions
Non-Alcoholic Steatohepatitis(NASH)
Interventions
Drug: Active treatment
Drug: Placebo
First Posted Date
2008-06-27
Last Posted Date
2009-08-13
Lead Sponsor
Pfizer
Target Recruit Count
9
Registration Number
NCT00706537
Locations
🇺🇸

Pfizer Investigational Site, Durham, North Carolina, United States

Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial

Phase 3
Completed
Conditions
Gaucher Disease
Interventions
First Posted Date
2008-06-27
Last Posted Date
2018-10-04
Lead Sponsor
Pfizer
Target Recruit Count
45
Registration Number
NCT00705939
Locations
🇨🇱

Pontificia Universidad Catolica de Chile, Santiago, Chile

🇦🇺

Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia

🇺🇸

Department of Human Genetics, Emory University School of Medicine, Decatur, Georgia, United States

and more 8 locations
© Copyright 2025. All Rights Reserved by MedPath